***05/05/2022 - An updated Clinical guide has been attached following publication.***
***24 February 2022: The ‘Clinical Guide -
Therapies for Patients Hospitalised Due to COVID-19’ published on 24 February 2022 has been added to this page. ***
***31 January 2022: The interim Clinical Commissioning Policy has been updated: Correction to wording in exclusion criteria and
cautions section of policy***
The published policy has been updated to reflect that the IL-6 inhibitor tocilizumab (RoActemra) is now licensed in the treatment of adult patients hospitalised due to COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation (please note that additional exclusion criteria now apply). Sarilumab (Kevzara), an off-label treatment, should continue to be considered where tocilizumab is not available or cannot be used.